Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease. (December 2021)

• Record Type: Journal Article
• Authors: Burel, Julie G.; Singhania, Akul; Dubelko, Paige; Muller, Julius; Tanner, Rachel; Parizotto, Eneida; Dedicoat, Martin; Fletcher, Thomas E.; Dunbar, James; Cunningham, Adam F.; Lindestam Arlehamn, Cecilia S.; Catanzaro, Donald G.; Catanzaro, Antonino; Rodwell, Timothy; McShane, Helen; O'Shea, Matthew K.; Peters, Bjoern
• Is Part Of: Tuberculosis. Volume 131(2021)
• Publication Date: 2021-12
• Subjects: Latent tuberculosis -- Blood transcriptomics -- Prophylaxis treatment; 616.995
• DOI: 10.1016/j.tube.2021.102127
• Languages: English
• ISSNs: 1472-9792

Abstract

Abstract: Although only a small fraction will ever develop the active form of tuberculosis (ATB) disease, chemoprophylaxis treatment in latent TB infected (LTBI) individuals is an effective strategy to control pathogen transmission. Characterizing immune responses in LTBI upon chemoprophylactic treatment is important to facilitate treatment monitoring, and thus improve TB control strategies. Here, we studied changes in the blood transcriptome in a cohort of 42 LTBI and 8 ATB participants who received anti-TB therapy. Based on the expression of previously published gene signatures of progression to ATB, we stratified the LTBI cohort in two groups and examined if individuals deemed to be at elevated risk of developing ATB before treatment (LTBI-Risk) differed from others (LTBI-Other). We found that LTBI-Risk and LTBI-Other groups were associated with two distinct transcriptomic treatment signatures, with the LTBI-Risk signature resembling that of treated ATB patients. Notably, overlapping genes between LTBI-Risk and ATB treatment signatures were associated with risk of progression to ATB and interferon (IFN) signaling, and were selectively downregulated upon treatment in the LTBI-Risk but not the LTBI-Other group. Our results suggest that transcriptomic reprogramming following treatment of LTBI is heterogeneous and can be used to distinguish LTBI-Risk individuals from the LTBI cohort at large.